Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29876714 | 0.93 | MAOA (0.42) | MAOAMAOBTNFMAPKAPK2GAA | |
| SCHEMBL30688778 | 0.81 | MAOA (0.55) | MAOAMAOBMAPKAPK2GAANPSR1 | |
| SCHEMBL79264 | 0.81 | MAOA (0.55) | MAOAMAOBMAPKAPK2GAANPSR1 | |
| SCHEMBL29370052 | 0.81 | MAOA (0.55) | MAOAMAOBMAPKAPK2GAANPSR1 | |
| Benzimidazole SCHEMBL28481892 | 0.81 | QPCT (0.33) | MAOAMAOBKDM4EHPGDMAPK10 | |
| Water SCHEMBL27261398 | 0.80 | MAOA (0.53) | MAOAMAOBMAPKAPK2GAANPSR1 | |
| SCHEMBL668167 | 0.77 | MAOA (0.50) | MAOAMAOBMAPKAPK2KDM4ECYP1A2 | |
| SCHEMBL31329296 | 0.77 | MAOA (0.50) | MAOAMAOBMAPKAPK2KDM4ECYP1A2 | |
| Xanthene SCHEMBL28326773 | 0.76 | MAOA (0.59) | MAOAMAOBTNFMAPKAPK2GAA | |
| SCHEMBL8515984 | 0.74 | MAOB (0.65) | MAOAMAOBTNFMAPKAPK2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | claimed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | claimed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | claimed |
| EP-1699450-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | Darpharma, INC. (US) | 2006-09-13 | — | — | EP | claimed |
| WO-2006012640-A2 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2005062894-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | DARPHARMA, INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-8318938-B2 | Trans-fused chromenoisoquinolines synthesis and methods for use | PURDUE RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318938-B2 | Trans-fused chromenoisoquinolines synthesis and methods for use | PURDUE RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318938-B2 | Trans-fused chromenoisoquinolines synthesis and methods for use | PURDUE RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2006012640-A3 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA INC (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090030025-A1 | TRANS-FUSED CHROMENOISOQUINOLINES SYNTHESIS AND METHODS FOR USE | PURDUE RESEARCH FOUNDATION (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030025-A1 | TRANS-FUSED CHROMENOISOQUINOLINES SYNTHESIS AND METHODS FOR USE | PURDUE RESEARCH FOUNDATION (US) | 2009-01-29 | — | — | US | disclosed |
| US-6413977-B1 | D1 AGONISTS; CENTRAL AND PERIPHERAL NERVOUS SYSTEM DYSFUNCTIONS; IMPROVING COGNITION AND MEMORY; PARKINSON'S DISEASE, SCHIZOPHRENIA, ATTENTION-DEFICIT HYPERACTIVITY, SUBSTANCE ABUSE, PHYSIOLOGICAL FUNCTION | PURDUE RESEARCH FOUNDATION | 2002-07-02 | — | — | US | disclosed |
| EP-1192161-A2 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6346536-B1 | BENZOPYRANOISOQUINOLONE DERIVATIVES; NEURODEGENERATIVE AND BRAIN DISORDERS; REPERFUSION INJURIES; ANTIISCHEMIC AGENTS | GUILFORD PHARMACEUTICALS INC. | 2002-02-12 | — | — | US | disclosed |
| US-6306889-B1 | FUSED HETEROCYCLIC DRUGS FOR CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2000078765-A2 | CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-1019409-A1 | POLY(ADP-RIBOSE) POLYMERASE (\"PARP\") INHIBITORS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURAL OR CARDIOVASCULAR TISSUE DAMAGE | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999011645-A1 | POLY(ADP-RIBOSE) POLYMERASE ('PARP') INHIBITORS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURAL OR CARDIOVASCULAR TISSUE DAMAGE | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | MAOA 296/4885MAOB 221/4885TNF 4527/4885 |
| US-20090030025-A1 | TRANS-FUSED CHROMENOISOQUINOLINES SYNTHESIS AND METHODS FOR USE | SLC6A3, HTR3B, SLC18A2 | MAOA 237/4885MAOB 147/4885TNF 4813/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | MAOA 734/4885MAOB 698/4885TNF 3897/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | MAOA 287/4885MAOB 213/4885TNF 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.